Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature

International Journal of Antimicrobial Agents

Volumn 46, Issue 1, 2015, Pages 8-12

  Di Bella, S ^a   Nisii, C ^a   Petrosillo, N ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

CDI; Clostridium; Clostridium difficile; Clostridium difficile infection; Tigecycline

Indexed keywords

CLINDAMYCIN; FIDAXOMICIN; METRONIDAZOLE; RIFAXIMIN; TIGECYCLINE; TOXIN; VANCOMYCIN; ANTIINFECTIVE AGENT; MINOCYCLINE;

ALLERGIC REACTION; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BACTERIUM ISOLATE; CASE STUDY; CAUSE OF DEATH; CLOSTRIDIUM DIFFICILE INFECTION; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; FECES; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLORA; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; REFRACTORY CLOSTRIDIUM DIFFICILE INFECTION; REVIEW; SPOOA GENE; SPOROGENESIS; TCDA GENE; TCDB GENE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CLOSTRIDIUM INFECTIONS; DIARRHEA; DRUG EFFECTS; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; HUMANS; MINOCYCLINE; TREATMENT OUTCOME;

EID: 84934903265     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.03.012     Document Type: Review

References (47)

1. Reveles KR, Lee GC, Boyd N.K., Frei CR. The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001-2010. Am J Infect Control 2014; 42:1028-32.
2. Freeman J, Bauer MP, Baines S.D., Corver J., Fawley WN, Goorhuis B, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23:529-49.
3. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004; 171:51-8.
4. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007; 13:1417-9.
5. Magill SS, Edwards JR, Bamberg W, Beldavs Z.G., Dumyati G., Kainer MA, et al. Multistate point-prevalence survey of health care-associated infections. NEngl J Med 2014; 370:1198-208.
6. He M, Miyajima F, Roberts P., Ellison L, Pickard DJ, Martin M.J., et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013; 45:109-13.
7. Baines SD, O'Connor R, Freeman J, Fawley W.N., Harmanus C., Mastrantonio P, et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62:1046-52.
8. Farne HA, Martin NK, Main J, Orchard T., Tyrrell-Price J. Creactive protein is a useful predictor of metronidazole treatment failure in mild-to-moderate Clostridium difficile infection. Eur J Gastroenterol Hepatol 2013; 25:33-6.
9. Jung KS, Park JJ, Chon Y.E., Jung ES, Lee HJ, Jang HW, et al. Risk factors for treatment failure and recurrence after metronidazole treatment for Clostridium difficile-associated diarrhea. Gut Liver 2010; 4:332-7.
10. Vardakas KZ, Polyzos KA, Patouni K, Rafailidis P.I., Samonis G., Falagas ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents 2012; 40:1-8.
11. Cohen SH, Gerding DN, Johnson S, Kelly C.P., Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-55.
12. Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20:1-26.
13. Surawicz CM, Brandt LJ, Binion D.G., Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108:478-98 (quiz 499).
14. Wilcox MH. Efficacy of tigecycline in complicated skin and skin structure infections and complicated intra-abdominal infections. J Chemother 2005; 17:23-9.
15. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006; 43:518-24.
16. Nagy E, Dowzicky MJ. In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Scand J Infect Dis 2010; 42:33-8.
17. Rashid MU, Lozano HM, Weintraub A, Nord CE. In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden. Anaerobe 2013; 20:32-5.
18. Kundrapu S, Hurless K, Sunkesula V.C., Tomas M., Donskey CJ. Tigecycline exhibits inhibitory activity against Clostridium difficile in the intestinal tract of hospitalised patients. Int J Antimicrob Agents 2015; 45:424-6.
19. Aldape MJ, Heeney DD, Bryant A.E., Stevens DL. Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile. J Antimicrob Chemother 2015; 70:153-9.
20. Garneau JR, Valiquette L, Fortier LC. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC Infect Dis 2014; 14:29.
21. Lachowicz D, Pituch H, Obuch-Woszczatynski P. Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012. Anaerobe 2015; 31:37-41.
22. Nuding S, Frasch T, Schaller M., Stange EF, Zabel LT. Synergistic effects of antimicrobial peptides and antibiotics against Clostridium difficile. Antimicrob Agents Chemother 2014; 58:5719-25.
23. Jump RL, Li Y, Pultz M.J., Kypriotakis G., Donskey CJ. Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production. Antimicrob Agents Chemother 2011; 55:546-9.
24. Lin YC, Huang YT, Tsai P.J., Lee TF, Lee NY, Liao CH, et al. Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in Taiwan. Antimicrob Agents Chemother 2011; 55:1701-5.
25. Hawser SP. Activity of tigecycline against recent European clinical isolates of Clostridium difficile. Int J Antimicrob Agents 2010; 35:97-8.
26. Lu CL, Liu CY, Liao C.H., Huang YT, Wang HP, Hsueh PR. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole. Int J Antimicrob Agents 2010; 35:311-2.
27. Noren T, Alriksson I, Akerlund T., Burman LG, Unemo M. In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden. Clin Microbiol Infect 2010; 16:1104-10.
28. Hecht DW, Galang MA, Sambol S.P., Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 51:2716-9.
29. Baines SD, Saxton K, Freeman J., Wilcox MH. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2006; 58:1062-5.
30. Edlund C, Nord CE. In-vitro susceptibility of anaerobic bacteria to GAR-936, a newglycylcycline. Clin Microbiol Infect 2000; 6:159-63.
31. Petersen PJ, Jacobus NV, Weiss W.J., Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738-44.
32. Nord CE, Sillerström E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006; 50:3375-80.
33. Bassis CM, Theriot CM, Young VB. Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection. Antimicrob Agents Chemother 2014; 58:2767-74.
34. Theriot CM, Schumacher CA, Bassis C.M., Seekatz AM, Young VB. The effects of tigecycline and vancomycin administration on established Clostridium difficile infection. Antimicrob Agents Chemother 2015; 59:1596-604.
35. Kim HB, Zhang Q, Sun X., Beamer G, Wang Y, Tzipori S. Beneficial effect of oral tigecycline treatment on Clostridium difficile infection in gnotobiotic piglets. Antimicrob Agents Chemother 2014; 58:7560-4.
36. Ochsner UA, Bell SJ, O'Leary AL, Hoang T, Stone K.C., Young CL, et al. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. J Antimicrob Chemother 2009; 63:964-71.
37. Mathur T, Kumar M, Barman T.K., Kumar GR, Kalia V, Singhal S, et al. Activity of RBx 11760, a novel biaryl oxazolidinone, against Clostridium difficile. J Antimicrob Chemother 2011; 66:1087-95.
38. Bossé D, Lemire C, Ruel J, Cantin AM, Ménard F, Valiquette L. Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection. Infection 2013; 41:579-82.
39. Britt NS, Steed ME, Potter E.M., Clough LA. Tigecycline for the treatment of severe and severe complicated Clostridium difficile infection. Infect Dis Ther 2014; 3:321-31.
40. Cheong EY, Gottlieb T. Intravenous tigecycline in the treatment of severe recurrent Clostridium difficile colitis. Med J Aust 2011; 194:374-5.
41. El-Herte RI, Baban TA, Kanj SS. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature. Scand J Infect Dis 2012; 44:228-30.
42. Fantin F, Manica A, Soldani F., Bissoli L, Zivelonghi A, Zamboni M. Use of tigecycline in elderly patients for Clostridium difficile infection. Geriatr Gerontol Int 2015; 15:230-1.
43. Herpers BL, Vlaminckx B, Burkhardt O., Blom H, Biemond-Moeniralam HS, Hornef M, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009; 48:1732-5.
44. Kopterides P, Papageorgiou C, Antoniadou A., Papadomichelakis E, Tsangaris I, Dimopoulou I., et al. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth Intensive Care 2010; 38:755-8.
45. Lao 2nd D, Chiang T, Gomez E. Refractory Clostridium difficile infection successfully treated with tigecycline, rifaximin, and vancomycin. Case Rep Med 2012; 2012:702910.
46. Metan G, Ture Z, Kaynar L., Berk E, Gursoy S, Alp E., et al. Tigecycline for the treatment of Clostridium difficile infection refractory to metronidazole in haematopoietic stem cell transplant recipients. J Chemother 2014 (1973947814Y0000000225) [Epub ahead of print].
47. Thomas A, Khan F, Uddin N., Wallace MR. Tigecycline for severe Clostridium difficile infection. Int J Infect Dis 2014; 26:171-2.